TIDMMTFB
RNS Number : 9356I
Motif Bio PLC
22 June 2017
22 June 2017
THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFERING OF ANY
SECURITIES. ANY OFFERING OF SECURITIES BY THE COMPANY IS NOT
ADDRESSED TO ANY PERSON WITH A REGISTERED ADDRESS IN, OR WHO IS
RESIDENT IN, THE UNITED STATES OR ANY U.S. PERSON, AND NO SUCH
PERSONS ARE ENTITLED TO PARTICIPATE IN ANY SUCH OFFERING.
This announcement does not constitute an offer to buy, acquire
or subscribe for (or the solicitation of an offer to buy, acquire
or subscribe for) Ordinary Shares in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such
jurisdiction.
Motif Bio plc
("Motif" or the "Company")
Result of General Meeting and Total Voting Rights
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, is pleased to
announce that all the resolutions set out in the circular dated 5
June 2017, including those necessary to implement the Placing to
raise GBP20 million, were duly passed at the General Meeting of the
Company held earlier today.
Following the passing of the resolutions, the Company has issued
and allotted (subject only to Admission) 66,666,667 new ordinary
shares of GBP0.01 each in the capital of the Company ("New Ordinary
Shares"). Application has been made to the London Stock Exchange
for the New Ordinary Shares to be admitted to trading on AIM and it
is expected that Admission will occur and that dealings will
commence at 8.00 a.m. on 23 June 2017.
The New Ordinary Shares will rank pari passu with the existing
ordinary shares of GBP0.01 each in the capital of the Company.
Following Admission, there will be 262,878,775 ordinary shares
of GBP0.01 each in the capital of the Company in issue, each
carrying one voting right. No shares are held in treasury. The
total number of voting rights in the Company is therefore
262,878,775. This number may be used by Shareholders as the
denominator for the calculation by which they will determine if
they are required to notify their interest in, or a change in their
interest in, the share capital of the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules.
Unless otherwise defined in this announcement, capitalised words
and phrases used in this announcement shall have the same meanings
given to them in the circular dated 5 June 2017.
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief
Executive Officer)
Peel Hunt LLP (NOMAD &
JOINT BROKER) + 44 (0)20 7418 8900
Dr. Christopher Golden
Oliver Jackson
Northland Capital Partners
Limited (JOINT BROKER)
Patrick Claridge/David
Hignell
John Howes/Rob Rees (Broking) +44 (0)20 3861 6600
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or motifbio@walbrookpr.com
PR & IR) Mob: +44 (0)7980 541 893
Paul McManus Mob: +44 (0)7900 608 002
Mike Wort
MC Services AG (EUROPEAN
IR)
Raimund Gabriel +49 (0)89 210 2280
Notes to Editors
About Motif Bio
Motif Bio is a clinical-stage biopharmaceutical company, engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalised patients caused by multi-drug resistant bacteria. Our
lead product candidate, iclaprim, is being developed for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP),
infections often caused by MRSA (methicillin-resistant
Staphylococcus aureus). Having completed the REVIVE-1 trial,
patients are currently being enrolled and dosed in a second global
Phase 3 clinical trial (REVIVE-2) with an intravenous formulation
of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2
is expected in the second half of 2017.
IMPORTANT INFORMATION
This announcement (and the information contained herein) does
not contain or constitute an offer of securities for sale, or
solicitation of an offer to purchase securities, in the United
States, Australia, Canada, Japan or the Republic of South Africa or
any other jurisdiction where such an offer or solicitation would be
unlawful. The securities referred to herein have not been and will
not be registered under the US Securities Act of 1933, as amended
(the "Securities Act") or with any securities regulatory authority
of any state or jurisdiction of the United States and may not be
offered, sold, resold, or delivered, directly or indirectly, in or
into the United States or to U.S. persons unless the securities are
registered under the Securities Act, or pursuant to an exemption
from, or in a transaction not subject to, the registration
requirements of the Securities Act, in each case in accordance with
any applicable securities laws and regulations of any state or
jurisdiction of the United States. The securities referred to
herein are being offered and sold (i) outside the U.S. to non-U.S.
persons in offshore transactions within the meaning of, and in
accordance with, Regulation S under the Securities Act and (ii) in
the U.S., pursuant to an exemption from, or in a transaction not
subject to, the registration requirements of the Securities Act.
There will be no public offer of securities in the United
States.
None of the Placing Shares, this announcement or any other
document connected with the Placing have been or will be approved
or disapproved by the US Securities and Exchange Commission or by
the securities commissions of any state or other jurisdiction of
the United States or any other regulatory authority, nor have any
of the foregoing authorities or any securities commission passed
comment upon or endorsed the merits of the offering of the Placing
Shares or the accuracy or adequacy of this announcement or any
other document connected with the Placing. Any representation to
the contrary is a criminal offence.
The Placing Shares have not been and will not be registered
under the securities laws and regulations of any jurisdiction, in
particular, Australia, Canada, Japan or the Republic of South
Africa, and may not be offered, sold, resold, or delivered,
directly or indirectly, within Australia, Canada, Japan or the
Republic of South Africa, or in any jurisdiction where it is
unlawful to do so, except pursuant to an applicable exemption.
This announcement contains "forward-looking statements" which
include all statements (other than statements of historical facts)
including, without limitation, those regarding the financial
position, business strategy, plans and objectives of management for
future operations of Company and its subsidiary undertakings (the
"Group"), and any statements preceded by, followed by or that
include the words "targets", "believes", "expects", "aims",
"intends", "will", "may", "anticipates", "would", "could" or
"similar" expressions or negatives thereof. Such forward-looking
statements involve known and unknown risks, uncertainties and other
important factors beyond the Company's control that could cause the
actual results, performance or achievements of the Group to be
materially different from future results, performance or
achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous
assumptions regarding the Group's present and future business
strategies and the environment in which the Group will operate in
the future. These forward-looking statements speak only as at the
date of this announcement. The Company expressly disclaims any
obligation or undertaking to disseminate any updates or revisions
to any forward looking statements contained herein to reflect any
change in the Company's expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statements are based unless required to do so by applicable law or
the AIM Rules for Companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMPGUQGQUPMGCP
(END) Dow Jones Newswires
June 22, 2017 10:20 ET (14:20 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024
